ⅠB期非小细胞肺癌术后预后因素分析
回顾性分析458例ⅠB期非小细胞肺癌根治术后患者,5年生存率为85.6%。单因素分析显示年龄≥65岁、术前CEA升高、术前FEV1%pred<70%、血管癌栓及低分化与预后不良相关(P<0.05);多因素分析显示术前CEA升高、术前FEV1%pred<70%及低分化为独立危险因素(P<0.05)。
要点
- 术前CEA升高、FEV1%pred<70%及低分化是ⅠB期非小细胞肺癌术后独立预后危险因素。
- 458例患者5年生存率为85.6%,其中66例死亡。
- 低分化肿瘤患者可能从术后化疗中获益。
核心结论
- 术前CEA升高、术前FEV1%pred<70%及低分化是影响ⅠB期非小细胞肺癌患者预后和生存率的独立危险因素。
- 低分化肿瘤患者可能从术后化疗中获益。
研究设计与样本
- 回顾性分析2009年1月至2010年12月行根治性切除(R0)且病理诊断为ⅠB期肺癌的458例患者临床资料。
- 其中男性269例,女性189例,年龄28至88岁,中位年龄61岁。
- 采用Kaplan-Meier法和Log rank检验进行单因素生存分析,Cox比例风险模型进行多因素生存分析。
主要发现
- 458例中66例死亡,5年生存率为85.6%。
- 单因素分析显示年龄≥65岁、术前CEA升高、术前FEV1%pred<70%、血管癌栓及低分化与预后不良相关(P<0.05)。
- 多因素分析显示术前CEA升高、术前FEV1%pred<70%及低分化与预后不良相关(P<0.05)。
关键数值与推荐
- 单因素分析中年龄≥65岁、术前CEA升高、术前FEV1%pred<70%、血管癌栓及低分化为预后不良因素(P<0.05)。
- 多因素分析中术前CEA升高、术前FEV1%pred<70%及低分化为独立预后危险因素(P<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To study the prognostic factors for patients with stage ⅠB non-small cell lung cancer (NSCLC) after radical operation (R0). Methods: The clinical data of 458 patients who underwent radical resection for NSCLC and were pathologically diagnosed with stage ⅠB lung cancer from January 2009 to December 2010, were reviewed retrospectively. Those cases include 269 male patients and 189 female, aged between 28 and 88, with a median age of 61 years. The Kaplan-Meier method and Log rank test were used for univariate survival analysis and the Cox proportional hazards model for multivariate survival analysis. Results: Among these 458 cases, 66 patients were dead and the 5-year survival rate was 85.6%.The results of the univariate analysis showed that the age ≥65 years, elevated preoperative CEA, preoperative FEV1%pred<70%, vascular carcinoma embolus, and low tumor differentiation were associated with poor prognosis of patients(P<0.05). The results of the multivariate analysis showed that elevated preoperative CEA, preoperative FEV1%pred<70% and low tumor differentiation were connected with poor prognosis of patients (P<0.05). Conclusions: Elevated preoperative CEA, preoperative FEV1%pred<70% and low tumor differentiation are independent risk factors which influence prognosis and survival rate of patients with stage ⅠB NSCLC, among which those with poorly differentiated tumor could benefit from postoperative chemotherapy.
引用
- Song P, Zang RC, Zhang MY, et al. [Analysis of prognostic factors for patients with stageⅠb non-small cell lung cancer after operation]. Zhonghua Zhong Liu Za Zhi. 2017. PMID: 28550671. doi:10.3760/cma.j.issn.0253-3766.2017.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。